How we deal with the problems uncovered herein is something for deliberate consideration, not the activity of an automaton. For example, this paper demonstrates that patents asserted by inventors and inventor based companies generally do not fare as well as patents of other entities. However, in the United States none of us would want to stop all such entities from trying to market and license their ideas. Most of us would agree that the independent inventor has been the heart of innovation in the United States for a very long time. We have too many memories of the stories of the Wright Brothers, Chester Carlton of Xerox fame, of Eli Whitney and the cotton gin, of Edison, and of Farnsworth — the farmer boy who invented the television.

While in the Solicitor’s Office at the USPTO Chen’s notable Federal Circuit arguments included In re Bilski, In re Nuijten, and In re Comiskey. While I disagreed with the Federal Circuit decision in each of those cases I still believe Chen to be an excellent choice for the Federal Circuit. While some may look at the cases where Chen defended the Board, that was his job and I would caution reading to much into the briefs filed looking for a window into the judicial philosophy of Chen. Indeed, I have every reason to expect that he will align himself with the pro-patent wing of the Court.

As can be seen from Fig. 12, 25% of the cases brought against the retailer were actually brought by Producer companies. The other 75% of cases could indeed be classified as NPE suits. However, of these suits, 30% were by independent inventor or independent inventor related companies, and the other 45% of cases were brought by other NPEs. Interestingly of the “other NPEs”, we found all of the patents asserted against this retailer were patents originally obtained from Producers. Of these patents, one-third came from big corporate America and the remaining two-thirds from smaller Producing companies. That means nearly 65% of this retailers troubles, which it directly attributes to “trolls” asserting bad patents, are actually related to patents that derived from Producing companies. Of its cases that was resolved, pacer suggests none were tried and each was mutually dismissed within 4 months to 13 months.

1. Reed Tech takes over USPTO Contract from Google. 2. Pharma Patent Settlements Saved $25.5 Billion for US Health System. 3. Coffee Analysis Smart Phone App for that Perfect Brew. 4.FDA Approves Brain Wave Test to Assess ADHD in Children. 5. CAFC Copaxone® Patent Ruling Allows May 2014 Generic Launch. 6. A Permanent Injunction in a Patent Infringement Case! 7. Post-Grant Proceedings Treatise Publishes.

WASHINGTON — The U.S. Department of Commerce today released a green paper on Copyright Policy, Creativity, and Innovation in the Digital Economy (Green Paper) to advance discussion on a set of policy issues critical to economic growth. The Green Paper discusses the goals of maintaining an appropriate balance between rights and exceptions as the law continues to be updated; ensuring…

Myth 4: Patents of NPEs fare much more poorly in reexamination proceedings brought during litigation than those of Producers. Truth: When one includes independent inventors and independent inventors in the mix of NPEs, the patents being asserted by NPEs may be said to fare slightly more poorly in reexamination proceedings than those patents asserted by Producers. However, if one removes these independent inventor entities from the mix of NPEs, the patents held by non-independent inventor based NPEs were seen to do at least as well, if not better, than the average asserted patent of the Producers which was likewise thrown into reexamination during litigation.

Design patents can cover one or more of the shape, color, ornamentation or texture of an object. Design patents claiming a shape typically have line drawings showing various views of the shape. Solid lines in the drawings are the claimed features of the shape. Broken lines in the drawings show what the rest of the object might look like. To determine infringement, it’s only necessary to compare the solid lines. The broken lines don’t count. Ironically, this means that the fewer solid lines in a design patent, or conversely, the more broken lines in a design patent, the stronger the patent.

There are many myths that are attached to the fable of the so-called “patent troll.” Acting like the MythBusters, we probed some of them. For example, the success rate of NPEs overall across 267 random cases indicates that the litigation outcome for NPE suits looks very similar to litigation outcome for Producer suits. However, when individual inventor suits and individual inventor company suits were removed from the mix of overall NPEs, we found that non-independent inventor NPEs had an outcome profile that looked significantly better than the Producers, both in very likely favorable and likely unfavorable outcomes in litigation.

United States Marine, Inc. (USM) sued the United States government in the United States District Court for the Eastern District of Louisiana under the Federal Tort Claims Act (FTCA), 28 U.S.C. § 1346(b) and 28 USC §2674. USM alleged that the United States misappropriated USM’s trade secrets. Specifically, USM claimed that the United States Navy, which had lawfully obtained USM’s proprietary technical drawings under a contract (to which USM was not a party), owed USM a duty of secrecy that it breached by disclosing those drawings to a rival private firm for use in designing military boats for the government.

Doctors and researchers are quietly acquiescing to the demands of those asserting copyright in medical tests, for fear of becoming entwined in lengthy and expensive legal proceedings that could result in a costly judgment. Such fear could easily become a self-fulfilling prophecy if it prompts the creation of an industry norm for licensing medical tests. Courts and legislators have been known to defer to industry custom, even when they harbor some doubts about the wisdom of the underlying logic. The challenging thread running through all of this is that medical tests of this kind stand at the boundary between patent and copyright, raising the mind-bending question of how to conceptualize a process, which is the purview of patent, when that process consists of nothing more than words, which is normally the purview of copyright.

Perhaps the most ridiculous suggestion given (step 8) is to download the free PTO Patent Bar Exam Review Package from CNET. The WikiHow article explains that this free package contains MPEP 8th edition revisions 1 and 2. Why would you ever want to even consider the 8th edition revisions 1 and 2 when you will be tested on the 8th edition revision 9? Revision 9 was published August 2012. Revision 1 was published February 2003 and revision 2 was published May 2004. Why would anyone who is at all serious use materials that are a decade old to take an exam that is constantly being updated and refreshed with new materials? If you study the wrong MPEP edition you have absolutely NO chance to pass the patent bar exam.

The FDA is following through on plans to issue a proposed rule to revise regulations to allow generic drugmakers to update labeling. The rule would update current regulations that prevent generic drugmakers from doing so, even if they become aware of a potential risk not mentioned in labeling. By contrast, brand-name drugamkers can update warnings and precautions on labeling before obtaining FDA approval. Additionally, Merck won an important court ruling for the entire pharmaceutical industry. A federal court decided that, under certain circumstances, drugmakers may defend themselves against product liability lawsuits by citing preemption.